Interfaces Based on Laser-Structured Arrays of Carbon Nanotubes with Albumin for Electrical Stimulation of Heart Cell Growth.

Successful formation of electronic interfaces between living cells and electronic components requires both good cell viability and performance level. This paper presents a technology for the formation of nanostructured arrays of multi-walled carbon nanotubes (MWCNT) in biopolymer (albumin) layer for higher biocompatibility. The layer of liquid albumin dispersion was sprayed on synthesized MWCNT arrays by deposition system.

Immune approaches in tuberculosis therapy: a brief overview.

TB is typically caused by Mycobacterium tuberculosis, a symbiotic bacterium present in one-third of the world's population. There any many factors triggering overt clinical disease in a small proportion of humans. In our view the major role in the process is played by the host's immune response, especially self-directed, destructive inflammation.

Analysis of the interferon status and cytokine profile in patients with genital herpes.

The present work is dedicated to the investigation and complete characterization of the interferon (IFN) and cytokine profile in 8 patients with genital herpes caused by the herpes simplex virus type 2 (HSV-2). The control group included 42 healthy individuals. The patients with genital herpes showed a significant reduction in the ability to produce IFN-alpha and a slight decrease in the ability to produce IFN-gamma.

Possibility for Combination of Human rIFN-alpha and rIFN-beta in Complex Immune Therapy of Multiple Sclerosis.

Six patients with an evident multiple sclerosis (MS) were observed in dynamics of long term immune therapy based on administration of rIFN preparations. One half of them received the therapy with rIFN-alpha. Three other patients received rIFN-beta administration that was interrupted, when sensitivity of blood cells to in vitro IFN-beta action was decreased; the trial was continued by rIFN-alpha courses.

Long-Term Study of Interferon System State in Patients with Multiple Sclerosis Received the Individual Immune Therapy with Human Recombinant IFN-alpha.

Three patients with an evident multiple sclerosis (MS) were observed in a dynamics of long-term immune therapy based on administration of rIFN-alpha preparation. Production of IFN-alpha and IFN-gamma by induced peripheral blood leukocytes (PBL) of the patients was tested simultaneously with detection of a response of PBL to in vitro IFN-alpha and IFN-beta priming action every 10th day of observation. It has been shown that positive clinical effect of rIFN-alpha therapy was associated with a partial restoration of initially decreased IFN-alpha and IFN-gamma production by PBL, and paralleled by increasing the cell IFN-alpha sensitivity.

Dynamics of Interferon System State Parameters during the Immune Therapy of Multiple Sclerosis: Individual Analysis.

Three patients with obvious multiple sclerosis (MS) were observed in a dynamics of immune therapy based on administration of rIFN-beta preparation. The ability to produce IFN-alpha and IFN-gamma by stimulated peripheral blood leukocytes (PBL) of the patients was tested simultaneously with detection of PBL response to the in vitro IFN-beta priming action on the every 10th day of observation. It has been shown that positive clinical effect of recombinant IFN-beta therapy was associated with a partial restoration of initially decreased IFN-beta and IFN-beta production by PBL, and paralleled by reducing the cell IFN-beta sensitivity.

Cell Interferon Sensitivity in Immunodeficiencies, Autoimmune and Allergic Diseases.

Novel approach is suggested to study interferon (IFN) system state in various immunopathological disorders. It is based upon measurement of IFN-alpha and/or IFN-gamma production by leukocytes primed with IFN-alpha or IFN-gamma respectively. Study of IFN-status parameters revealed a tendency to decrease in the induced IFN-alpha production in patients with secondary immune deficiency (SID), autoimmune syndrome (AIS), allergic diseases, lymphoadenopathy (LAP), chronic bronchitis (CB) and bronchial asthma (BAS).